Bolt Biotherapeutics, Inc. - 8-K Filing
Bolt Biotherapeutics reported first-quarter 2026 financial results with $26K in collaboration revenue and a net loss of $7.2M compared to $1.2M revenue and $11.0M loss for the same quarter in 2025. The company had cash, cash equivalents, and marketable securities totaling $23.9 million as of March 31, 2026, which is expected to fund operations into 2027. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $BOLT